



Mouse Endostatin Competitive EIA Kit


U.S. Patent No.: 5,587,294 /// European Patent No.: EP 0 598 758 B1

Cat. #AC-615

SPECIFICATIONS

Determinations:	96
No. of Samples:	42 in duplicate
Assay Time:	4.0 hours
Sensitivity:	1.953 ng/ml
Dynamic Range:	1.953 ng/ml to 500 ng/ml
Intraassay Error:	<10%
Interassay Error:	<10%
Crossreactivity:	<2% Cross-reactivity with the following protein panel: Human: IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IP-10, EGF, EMAP-2, Endostatin, FGF-a, FGF-b, GM-CSF, G-CSF, M-CSF, IFN alpha, IFN-gamma, Leptin, MCP-1, MCP-2, MCP-3, MIP-1 alpha, MIP-1 beta, PDGF, PSA, Rantes, SCF, TGFa, TSP-1, TNF alpha, TNF beta, VEGF. Mouse: IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, GM-CSF, G-CSF, IFN-gamma, M-CSF, TNF alpha, VEGF.
Validation By:	Parallelism and Quantitative Recovery
Sample Matrix:	Tissue culture supernatants and biological fluids
Storage:	4°C
Assay Temp:	Room Temperature

ACCUCYTE® Mouse Endostatin Standard Curve



Published References:

1. Schmitz, V., et al., "Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice." *Gut*, 2004; 53: 561-567.
2. Hutter, R., et al., "Decreased reendothelialization and increased neointima formation with endostatin overexpressed in a mouse model of arterial injury." *Circulation*, 2003; 107: 1658-1669.



3. Oga, M., et al., "Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene." Intl. Journal of Oncology, 2003; 23:73-79.
4. Fukai, N., et al., "Lack of collagen XVIII/endostatin results in eye abnormalities." The EMBO Journal, 2002; 21(7): 1535-1544.
5. Kuo CJ, et al., "Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer." Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4605-10.
6. Jouanneau, E., et al., "Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model." January 2001; 51(1): 11-18.
7. Ratel, D. et al., "Antibodies to endostatin in a multifocal glioblastoma patient." The Lancet (Nov. 11, 2000), Vol. 356: 1656-1657.
8. Chen CT, et al., "Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin." Hum Gene Ther. 2000 Sep 20;11(14):1983-96.
9. Libutti, S.K. and Feldman, A.L. Letters to the Editor, Cancer Research (March 1, 2000), Vol. 60:1463-1464.
10. Chen, Q.R. et al., "Liposomes Complexed to Plasmids Encoding Angiostatin and Endostatin Inhibit Breast Cancer in Nude Mice." Cancer Research (July 15, 1999), Vol. 59: 3308-3312.
11. Blezinger, P. et al., "Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene." Nature Biotechnology (April 1999), Vol. 17: 343-348.